Sugi Predict

Sugi Predict / Targets / DNMT3A

DNMT3A

DNA (cytosine-5)-methyltransferase 3A · Q9Y6K1 · DNMT3A on Sugi Atlas →

11,627 patent compounds predicted against DNMT3A, 8,579 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL669669 SCHEMBL669669 0.66 7/20
SCHEMBL686753 SCHEMBL686753 0.50 7/20
SCHEMBL682916 SCHEMBL682916 0.60 6/20
SCHEMBL1427845 SCHEMBL1427845 0.58 6/20
SCHEMBL670281 SCHEMBL670281 0.52 6/20
SCHEMBL683733 SCHEMBL683733 0.50 6/20
SCHEMBL529326 SCHEMBL529326 0.73 5/20
SCHEMBL678697 SCHEMBL678697 0.58 5/20
SCHEMBL716546 SCHEMBL716546 0.52 5/20
SCHEMBL936997 SCHEMBL936997 0.51 5/20
SCHEMBL684097 SCHEMBL684097 0.50 5/20
SCHEMBL679214 SCHEMBL679214 0.61 4/20
SCHEMBL847681 SCHEMBL847681 0.55 4/20
SCHEMBL1428062 SCHEMBL1428062 0.54 4/20
SCHEMBL678601 SCHEMBL678601 0.53 4/20
SCHEMBL682900 SCHEMBL682900 0.53 4/20
SCHEMBL715864 SCHEMBL715864 0.48 4/20
SCHEMBL1427508 SCHEMBL1427508 0.48 4/20
SCHEMBL720201 SCHEMBL720201 0.43 4/20
SCHEMBL170830 SCHEMBL170830 0.63 3/20

Clinical trials — most relevant to DNMT3A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC PHASE3UNKNOWN
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR PHASE3NOT_YET_RECRUITING
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome PHASE1/PHASE2COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker PHASE2NOT_YET_RECRUITING
Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) PHASE1/PHASE2RECRUITING
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations PHASE2SUSPENDED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I, Dose Escalation Study of Decitabine PHASE1COMPLETED
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer PHASE1SUSPENDED
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors PHASE1COMPLETED
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome PHASE1COMPLETED
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) PHASE1RECRUITING
Effect of DNMT SNPs on DNA Methylation in Primary ITP nanUNKNOWN
DNA Methylation and Perioperative Pain Treatment nanCOMPLETED
A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL nanRECRUITING
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB) nanCOMPLETED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care nanCOMPLETED
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction nanNOT_YET_RECRUITING
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction nanRECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Biomarker Study of Chemotherapy Resistance and Outcomes in Samples From Older Patients With Acute Myeloid Leukemia nanCOMPLETED
Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a DNMT3A binder may also engage these)

ProteinNameSimilarity
O88508 — 1.000 O88508 →
Q1LZ53 — 1.000 Q1LZ53 →
Q4W5Z4 — 0.996 Q4W5Z4 →
G3MWR8 — 0.965 G3MWR8 →
Q7RTP6 — 0.960 Q7RTP6 →
Q8CJ19 — 0.960 Q8CJ19 →
D3Z7P3 — 0.946 D3Z7P3 →
GLS Glutaminase kidney isoform, mitochondrial 0.942 landscape →
P13264 — 0.940 P13264 →
Q9ERA0 — 0.939 Q9ERA0 →
Q5NVP9 — 0.939 Q5NVP9 →
Q6AYU1 — 0.938 Q6AYU1 →
Q6DN14 — 0.937 Q6DN14 →
PTPN1 Tyrosine-protein phosphatase non-receptor type 1 0.937 landscape →
Q9QY36 — 0.937 Q9QY36 →
Q12800 — 0.937 Q12800 →
Q5SQY2 — 0.937 Q5SQY2 →
P60762 — 0.936 P60762 →
F1QH17 — 0.936 F1QH17 →
Q62599 — 0.936 Q62599 →
Q2KI14 — 0.936 Q2KI14 →
NAA10 N-alpha-acetyltransferase 10 0.935 landscape →
Q4V8K3 — 0.935 Q4V8K3 →
Q8NBA8 — 0.935 Q8NBA8 →
MORF4L1 Mortality factor 4-like protein 1 0.934 landscape →
Q5RCB7 — 0.934 Q5RCB7 →
Q7T2U9 — 0.933 Q7T2U9 →
X2JAU8 — 0.933 X2JAU8 →
E9PV86 — 0.933 E9PV86 →
Q9NP50 — 0.932 Q9NP50 →